Gilead Sciences, Inc. (NASDAQ:GILD) Announces Dividend Increase – $0.82 Per Share

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, February 10th. Shareholders of record on Friday, March 13th will be paid a dividend of 0.82 per share by the biopharmaceutical company on Monday, March 30th. This represents a c) annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, March 13th. This is a 3.8% increase from Gilead Sciences’s previous quarterly dividend of $0.79.

Gilead Sciences has increased its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend every year for the last 10 years. Gilead Sciences has a dividend payout ratio of 37.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $8.11 per share next year, which means the company should continue to be able to cover its $3.16 annual dividend with an expected future payout ratio of 39.0%.

Gilead Sciences Trading Up 5.7%

Shares of Gilead Sciences stock traded up $8.34 on Wednesday, reaching $155.57. The company had a trading volume of 7,920,212 shares, compared to its average volume of 7,844,875. The firm’s 50 day moving average price is $128.39 and its two-hundred day moving average price is $121.53. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The firm has a market cap of $193.01 billion, a PE ratio of 24.12, a PEG ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the firm earned $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GoalVest Advisory LLC lifted its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the third quarter valued at approximately $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $27,000. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Finally, Financial Consulate Inc. grew its position in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.